QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Vaccine

Volumn 19, Issue 15-16, 2001, Pages 2080-2091

  Evans, Thomas G ^a,k   McElrath, M Juliana ^b   Matthews, Tom ^c   Montefiori, David ^c   Weinhold, Kent ^c   Wolff, Mark ^d   Keefer, Michael C ^a   Kallas, Esper G ^a   Corey, Larry ^b   Gorse, Geoffrey J ^e   Belshe, Robert ^e   Graham, Barney S ^f   Spearman, Paul W ^f   Schwartz, David ^g   Mulligan, Mark J ^h   Goepfert, Paul ^h   Fast, Patricia ⁱ   Berman, Phi ^j   Powell, Michael ^j   Francis, Don ^j  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMMES CORPORATION   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j VaxGen Inc   (United States)

^k PSSB   (United States)

more..

Author keywords

gp120 HIV 1MN protein; Immunization; QS 21

Indexed keywords

ALUMINUM HYDROXIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; QS 21; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG MEGADOSE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SYNCOPE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AIDS VACCINES; ALUMINUM HYDROXIDE; ANIMALS; CHO CELLS; CRICETINAE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MIDDLE AGED; SAFETY; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0035961455     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00415-1     Document Type: Article

References (48)

1. Adjuvants and immune enhancement
2. Paracrine cytokine adjuvants in cancer immunotherapy
3. Adjuvants for human vaccines-current status, problems and future prospects
4. Role of adjuvants in HIV vaccine design
5. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases
6. Saponins as vaccine adjuvants
7. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex
8. QS-21: A water soluble triterpene glycoside adjuvant
9. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy
10. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses
11. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations
12. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates
13. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses
14. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi
15. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs
16. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons
17. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection
18. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant
19. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine
20. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
21. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines
22. AIDSVAX (MN) in Bangkok injecting drug users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization
23. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
24. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
25. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
26. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
27. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
28. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP- PE/MF59
29. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
30. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1
31. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines
32. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients
33. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
34. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
35. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine
36. Detection of intracellular antigen-specific cytokines in human T cell populations
37. Human rabies in India: Epidemiological features, management and current methods of prevention
38. Intradermal hepatitis B vaccination
39. Low-dose intradermal and intramuscular vaccination against hepatitis B
40. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21
41. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
42. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells
43. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
44. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines
45. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
46. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
47. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes
48. Adjuvant activity of saponin: Antigen localization studies